Intellia Therapeutics, Inc.
NTLA
$9.20
-$0.40-4.17%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -525.91M | -519.02M | -522.28M | -508.80M | -485.50M |
| Total Depreciation and Amortization | 10.27M | 10.29M | 10.19M | 9.87M | 9.44M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 155.67M | 147.98M | 142.41M | 136.33M | 115.93M |
| Change in Net Operating Assets | -17.18M | 11.88M | 12.95M | -10.68M | -45.28M |
| Cash from Operations | -377.15M | -348.88M | -356.74M | -373.28M | -405.42M |
| Capital Expenditure | -4.01M | -5.78M | -6.32M | -9.37M | -12.66M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 218.00M | 131.35M | 26.26M | 116.52M | 109.46M |
| Cash from Investing | 213.99M | 125.57M | 19.94M | 107.15M | 96.80M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 125.76M | 185.75M | 289.91M | 226.82M | 188.09M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 125.76M | 185.75M | 289.91M | 226.82M | 188.09M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -37.40M | -37.57M | -46.88M | -39.31M | -120.52M |